Editing an α-globin enhancer in primary human hematopoietic stem cells as a treatment for β-thalassemia

Editing an α-globin enhancer in primary human hematopoietic stem cells as a treatment for β-thalassemia

β-thalassemia is characterised by the presence of an excess of α-globin chains, which contribute to erythrocyte pathology. Here the authors use CRISP/Cas9 to reduce α-globin expression in hematopoietic precursors, and show effectiveness in xenograft assays in mice.

Bibliographic Details
Main Authors: Sachith Mettananda, Chris A. Fisher, Deborah Hay, Mohsin Badat, Lynn Quek, Kevin Clark, Philip Hublitz, Damien Downes, Jon Kerry, Matthew Gosden, Jelena Telenius, Jackie A. Sloane-Stanley, Paula Faustino, Andreia Coelho, Jessica Doondeea, Batchimeg Usukhbayar, Paul Sopp, Jacqueline A. Sharpe, Jim R. Hughes, Paresh Vyas, Richard J. Gibbons, Douglas R. Higgs
Format: Article
Language:English
Published: Nature Publishing Group 2017-09-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-017-00479-7

Internet

https://doi.org/10.1038/s41467-017-00479-7

Similar Items